Re-shaping Global BioPharma Landscape through Continuing Innovation

June 28 and 29

Sino-American Pharmaceutical Professionals Association – Greater Philadelphia

Co-Organizers

Penn University of Pennsylvania

DIA www.diahome.org
Greetings from Conference Co-Chairs


With the theme “Re-shaping Global BioPharma Landscape through Continuing Innovation”, this conference will focus on the innovative medicine in emerging markets, translational R&D and personalized medicine, and innovative drug R&D. In the past years, continued waves of restructuring and globalization in pharmaceutical industry are presenting unprecedented challenges and opportunities. We are preparing for the impact of these changes on our communities and members. As the platform for exchange and promotion between US and China, SAPA-GP has played and will continue to play vital roles in connecting the biotechnology and pharmaceutical industries between the two countries.

In addition, SAPA-GP strives to continuously serve our members with high quality scientific programs, member events, and career development workshops. As a member of the SAPA-GP, you are among an exclusive global community of pharmaceutical professionals who aspire to do great things despite the constant change and challenging environment.

We thank all our sponsors for joining us on this dauntless journey. We thank all our members, volunteers and supporters for their vital contributions. With your continued support, together we will make SAPA-GP an even better community to promote fellow members interest and fulfill our stated mission.

Sean Zhang, MD, FCP
SAPA-GP President, Conference Co-Chair

Weiguo Dai, PhD
SAPA-GP President-Elect, Conference Co-Chair
1:30 – 2:00 PM  
Check-in and Networking

2:00 PM – 2:10 PM  
Opening Remarks  
Sean Zhang, MD, FCP  
President, SAPA-GP; Medical Director and Liaison to BMS China R&D, DMCP, Bristol-Myers Squibb

2:10 – 2:25 PM  
SAPA-GP Presidential Candidates: Introduction and Q&A  
Moderator:  
Weiguo Dai, PhD  
President-Elect, SAPA-GP, Scientific Director/Janssen Fellow, Drug Product Development, Johnson and Johnson

Session I: Innovative Medicine in Emerging Markets  
2:25 – 4:00 PM

Moderators:  
Xi-Yong (Sean) Fu, PhD, MBA  
Director, Financial Services and Operations, Merck & Co., Inc.  
Weiguo Dai, PhD  
President-Elect, SAPA-GP, Scientific Director/Janssen Fellow, Drug Product Development, Johnson and Johnson

2:25 – 3:00 PM
Keynote Address
R&D Capability and Capacity in Emerging Market
RuiPing Dong, MD, PhD
Senior Vice President, Head of Emerging Markets R&D, Merck & Co.

3:00 PM – 3:20 PM
Engaging with China: Penn Wharton China Center
Jeff Bernstein
Managing Director of the Penn-Wharton China Center, University of Pennsylvania

3:20 – 3:40 PM
Accelerating Innovation in a Collaborative Biopharma Ecosystem
Richard Soll, PhD
Senior Vice President, Integrated Services and Head, Corporate Alliances, WuXi AppTec

3:40 – 4:15 PM
Keynote Address
Ecosystem of Innovation: Strategic Partnerships in Emerging Markets
Salomon Azoulay, MD
Senior Vice President, Head of Medical & Development Emerging Markets & Established Products Business Units, Pfizer

Panel Discussion: Achieving Successes in a Changing Industry
- Science, Business, Career Choices and More

4:15 - 5:15 PM

Moderators:
Zak Huang, MD
Director, Worldwide Regulatory Affairs, Merck & Co., Inc.
Laura Hong, MD, PhD
Immediate Past President, SAPA-GP & Senior Research Scientist, Merck & Co., Inc.

4:15-4:35 pm
Introductory Remarks: Career Journey
James Boyd, PhD
Vice President, Global Regulatory Affairs, Sanofi

Panelists:
James Boyd, PhD
Vice President, Global Regulatory Affairs, Sanofi
Feng (Frank) Li, PhD
President and Co-Founder, Alliance Pharma, Inc.
Zhihe (Zeke) Li, MD, PhD
Senior Vice President, Corporate Development and Global Project Management, Frontage

Peng Wang, PhD
President, R&D, Yabao Pharmaceutical Group

PK Yegneswaran, PhD
Vice President, Global Technical Operations, Merck & Co., Inc.

Litao Zhang, PhD
Vice President, Lead Discovery, Lead Profiling, Lead Evaluation, Mechanistic Biochemistry & Compound Management, Bristol-Myers Squibb

Cocktail Reception
大费城美中医药协会欢迎酒会

(Complimentary to All Registered Attendees and Speakers)

5:15 – 6:00 PM
Opening Night Gala
大费城美中医药协会晚宴
6:00 – 10:00 PM

Masters of Ceremony:
Mabel Ju, MBA, MS
Financial Analyst, Merck & Co., Inc.
Joe Powers, PhD, MBA
Managing Director, Global Strategic Partnerships at University of Pennsylvania

6:00 – 6:10 PM
Special Remarks
Dongbai Ye (叶冬柏)
Science and Technology Counselor, Consulate General of P. R. China in New York (中国驻纽约总领事馆科技参赞)

6:10 - 6:30PM
Keynote Address
Academia and Industry - Circling the Dance Floor
Glen Gaulton, PhD
Chief Scientific Officer and Executive Vice Dean, Professor of Pathology and Laboratory of Medicine at the University of Pennsylvania, Perelman School of Medicine

6:30 – 6:45 PM
SAPA-GP Year in Review
Sean Zhang, MD, FCP
President, SAPA-GP; Medical Director and Liaison to BMS China R&D, DMCP, Bristol-Myers Squibb

6:45 – 7:15 PM
Award Ceremony

7:15 – 7:45 PM
Live Music Performance by
Ba Ban Chinese Music Society of New York

7:45 – 10:00 PM
Dinner and Networking
Featuring Live Music Performance by

**Ba Ban Chinese Music Society of New York**

纽约八板中乐团

Named after an ancient piece of folk music, "Ba Ban" literally means "Eight Beats" which is the structural basis for the grouping of notes in traditional Chinese music. The ensemble includes highly accomplished professional artists who have performed in concert halls around the world. Since its founding in 1999, the ensemble has performed frequently in Carnegie Hall, Lincoln Center, the Metropolitan Museum of Art, Harvard, Princeton, Yale, and among others. A few recent highlighted performances include their appearance before thousands of New York Met fans and their principle pipaist being performed as a featured solo artist with the New York Philharmonic.
Saturday, June 29, 2012

8:30 – 9:00 AM
Check-in and Networking

Morning Session

9:00 AM – 12:00 PM

9:00 – 9:10 AM
Welcome Remarks
Sean Zhang, MD, FCP
President, SAPA-GP; Medical Director and Liaison to BMS China R&D, DMCP, Bristol-Myers Squibb

Session II: Translational R&D and Personalized Medicine

Moderators:
Aston Liu, PhD
Senior Manager, Biopharm R&D, GlaxoSmithKline
Tianjing (TJ) Hu, PhD
Scientific Liaison, moksha8 Pharmaceuticals, Inc.

9:10 – 9:45 AM
Keynote Address
Drug Development in Rare Diseases Area
Carlo Russo, MD
Senior Vice President, Alternative Development Program, Development Head of Alternative Discovery and Development & Interim Head, Rare Disease R&D, GlaxoSmithKline

9:45 – 10:05 AM
Personalized Medicine: The Next Generation
Steve Z. Sun, PhD
CEO and Chairman, Genewiz

10:05 – 10:25 AM
Personalized Medicine Overview: Now and the Future
Sean Hu, PhD, MBA
Special Representative of Personalized Medicine Consortium, & Managing Partner and Head, Bionest Partners (USA)

10:25 – 10:45 AM
Coffee Break Sponsored by

10:45 - 11:20 AM
Keynote Address
The Role of Clinical Pharmacology in Drug Development
Edward Dennis Bashaw, PharmD.
Division Director, Division of Clinical Pharmacology-3, Office of Clinical Pharmacology, Office of Translational Sciences, US Food and Drug Administration

11:20 – 11:40 AM
Trans-Omics Solutions Catalyzing Drug R&D
Yingrui Li
CEO, BGI Americas Corp. & CEO, BGI Tech Solutions, Co. Ltd.

11:40 AM – 12:00 PM
How One Company Sees the Biomarker Development Pipeline and its Challenges?
Steven Averbuch, MD
Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb

Lunch
(Complimentary to All Registered Attendees and Speakers)
12:00 – 1:00 PM

Afternoon Session
1:00 – 4:15 PM

Panel Discussion: Innovation and Capital - The Business of BioScience
(Co-Organized with BayHelix)

Moderators:
Haishan Xiong, PhD, MBA
President and Co-founder, Vitalico LLC
Jichao (Jay) Kang, PhD
Director, Analytical Development & Formulation, Laureate Biopharma

Panelists:
Dahai Guo, MS, MBA
CEO and Founder, PuraCap Pharmaceuticals
Session III: Innovative Drug R&D

Moderators:
Jing Yang, PhD
Senior Principal Scientist, Discovery Biology, Bristol-Myers Squibb
Yin Liang, MD, PhD
Scientific Director/Janssen Fellow, Johnson and Johnson

2:00 – 2:35 PM
Keynote Address
The Rising of China Domestic Pharmas and their Challenges of Clinical Development
Joan Huaqiong Shen, MD, PhD
Chief Medical Officer, Hengrui Pharmaceutical Co., LTD
Former Vice President, SAPA-GP

2:35 – 2:55 PM
Millamolecular Chemistry as an Approach to Modulating Protein/Protein Interactions
Percy H. Carter, PhD
Executive Director, Immunology Medicinal Chemistry, Bristol-Myers Squibb

2:55 – 3:15 PM
Coffee Break, Networking, Exhibit Booth Viewing

3:15 – 3:50 PM
Keynote Address
Novel Biologics for Respiratory and Autoimmune Diseases
Zhengbin (Bing) Yao, PhD
Senior Vice President and Head, Innovative Medicine, MedImmune, AstraZeneca

3:50 – 4:00 PM
Closing Remarks
Weiguo Dai, PhD
President-Elect, SAPA-GP, Scientific Director/Janssen Fellow, Drug Product Development, Johnson and Johnson

4:00 – 4:15 PM
Raffle Drawing
Steven Averbuch, MD
Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb

Dr. Averbuch is currently Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company based in Lawrenceville, NJ, USA. In this role, Steve serves as the Executive Sponsor of the Translational R&D teams across the Full Development and Life Cycle Management pipeline while working to optimize knowledge sharing and biomarker tools across all of R&D to achieve stratified medicine development. Steve also leads the Pharmacodiagnostics Center of Excellence with its mission to drive strategy and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to BMS products.

Steve joined BMS in 2006. Previously he co-led the Oncology early strategy team and he was the executive sponsor for Oncology Transition Teams for the execution of Phase 2 Oncology programs. He has made significant Global Clinical Research contributions to business development and he has participated in seven successful acquisitions.

Steve previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.

Dr. Averbuch has authored over 60 peer reviewed publications and book chapters and he is a co-author on one patent. He is currently on the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations.

Salomon Azoulay, MD
Senior Vice President, Head of Medical & Development Emerging Markets & Established Products Business Units, Pfizer

Dr. Sam Azoulay is Senior Vice President, Medical & Development Emerging Markets & Established Products Business Units. Dr. Azoulay has led the Medical & Development of Emerging Markets Business Unit since November 2008. Most recently, in September 2011, Dr. Azoulay’s responsibilities expanded to include oversight of Clinical Development & Medical Affairs for the Established Products Business Unit.

Dr. Azoulay joined Pfizer as a result of the company’s acquisition of Parke Davis, Warner Lambert in 2000, where he had served as Development Site Head in Eastleigh, UK and Head of Cardiovascular for International. Following the merger with Pfizer, Dr. Azoulay moved to the US Pfizer Global Research & Development (PGRD) headquarters in New London, CT, as Vice President, Global Project Management, in charge of the cardiovascular and infectious disease portfolio. In 2003, he lead the varenicline (Champix) smoking cessation program up to its filing in the US and EU. In early 2006, Dr.
Azoulay moved to Tokyo, PGRD to lead the Development organization where he supervised 400 colleagues and was accountable for a number of approvals and submissions of major products. In April 2008, Dr. Azoulay was appointed Development Lead for the CardioVascular Metabolic and Endocrine Disease (CVMED) Research Unit.

Before joining Parke Davis, Sam served as Cardiovascular Head, and previously as Medical Manager, for Houde Labs, Hoechst Roussel, in Paris, France. Later, he served as head of the cardiovascular division and head of the Development Operations group of Pierre Fabre Labs in Paris, where he played an integral role in the development of the European organization. He also briefly worked as Senior Medical Director in Basel, Switzerland, for Roche.

Upon completion of his internship, Sam received his medical degree with a specialization in cardiology from Paris University. He also holds a DESS (MBA) from La Sorbonne, Paris.

Edward Dennis Bashaw, PharmD.
Division Director, Division of Clinical Pharmacology-3, Office of Clinical Pharmacology, Office of Translational Sciences, US Food and Drug Administration

Dr. Bashaw is currently the Director of the Division of Clinical Pharmacology-3 at the FDA. In this position he oversees the Clinical Pharmacology support of the Division of Dermatologic and Dental Drugs; the Division of Reproductive, Urologic and Bone Mineralization Drug Products; and the Division of Gastrointestinal and Inborn Errors of Metabolism. In his 25 yrs at the FDA he has been a primary reviewer, team leader, and a deputy division director across a number of therapeutic areas including, but not limited to neuropharmacology, surgical drugs, anti-inflammatory, over-the-counter, and pulmonary drugs in addition to his current responsibilities.

He received his BSPharm. and Pharm.D. from the University of Kentucky in 1986. Upon graduation Dr. Bashaw, completed a general residency at the National Institutes of Health Clinical Center in Bethesda, MD. At the conclusion of his residency he accepted a commission in the US Public Health Service and joined the FDA's Division of Biopharmaceutics in the area of neuropharmacology.

He is a recognized clinical pharmacology subject matter expert in the development of FDA policies related to orphan drug development, dermal/transdermal drug delivery, and policies related to analytical methodology. He most recently served as the Office of Clinical Pharmacology’s representative on the FDA's Cetero Working Group and helped draft the Agency’s validation strategy for the data. His research interests include the use of microneedles in dermal drug delivery and the “informational resource management” of orphan drug data.

As an officer in the US Public Health Service, Dr. Bashaw has been deployed in support of disaster relief efforts for four hurricanes, including Katrina. In addition he has been deployed to support other “national interest” gatherings including the Super Bowl and the State of the Union Address.

Jeff Bernstein
Managing Director of the Penn-Wharton China Center, University of Pennsylvania

Jeffrey Bernstein was appointed by Penn President Dr. Amy Gutmann as the Managing Director of the Penn Wharton China Center in September 2012, the first footprint for the entire University of Pennsylvania outside of Philadelphia, Pa. since
its founding in 1740 by renown scientist, philosopher, and statesman, Benjamin Franklin. The Center will engage China in the University’s academic and alumni activities, staying true to Penn’s tradition of integrating research across different disciplines and also having “real world” impact for the betterment of society. The aim of the center is to deepen US-China ties, as well as facilitate partnerships with Chinese academic, business, government, and independent research organizations, in the creation of dissemination of knowledge.

Served as Founder and Managing Director of Emerge Trade Services Co., Ltd., a US invested and Shanghai based company with three major businesses: Logistics Operations, Distribution, and Consulting. Over the past 13 years, Emerge has supported scores of Global Fortune 500 as well as Small to Medium Sized US companies as they penetrate the China market and establish distribution channels.

In 2010, Jeffrey Bernstein was appointed as the Independent Representative for the State of Nevada’s Commission on Economic Development, responsible for Eastern and Central China. The Commission’s focus activities include promoting job generating bilateral investment and leveraging Nevada’s leadership in trade shows, minerals, advanced energy, distribution logistics and aeronautics to spur economic growth. In 2006, Jeffrey Bernstein founded the Ohio China Center on behalf of the State of Ohio to provide export promotion services to Ohio manufacturers (mainly Small to Medium Sized Enterprises) aiming to sell to China. In addition, the Center educates Chinese Companies about making successful overseas investments.

Jeffrey Bernstein served as the elected Chairman of the Board of the American Chamber of Commerce in Shanghai (the largest American Chamber in Asia) in 2005 and 2006. The Shenzhen Stock Exchange qualified Jeffrey Bernstein as its first foreign ‘Independent Director’ and he now serves as an independent director on the Board of Hunan Valin Steel Co., Ltd, China’s 6th largest Steelmaker, and Arcelor Mittal’s largest investment in China. In his work as an independent director, Jeffrey Bernstein has made strides to affect tangible improvements in corporate governance, health, safety, and environmental performance.

Jeffrey Bernstein was honored with the 2007 Magnolia Silver Award from Shanghai Municipal Government for his significant contributions to the community. Jeffrey Bernstein has lived in China for 18 years and speaks fluent Mandarin. He graduated from the University of Pennsylvania, Wharton School with a B.S. in Economics, and frequently appears as a special expert and commentator on business talk shows produced by Shanghai Media Group subsidiary, CBN.

James Boyd, PhD
Vice President, Global Regulatory Affairs, Sanofi

James was born and educated in Ireland/England (PhD in Pharmacy and MBD). He joined the pharmaceutical company Merrill Dow (now Sanofi) in England in 1986, moved with the company to Kansas City Mo. in 1993, and then to Bridgewater NJ in 1996. He is currently Vice President in the Global Regulatory Affairs department, Sanofi Pharmaceuticals.

In addition to his pharmaceutical career, James is also a qualified Personal & Professional Coach (trained through Coach University and certified through The International Coaching Federation) and plans to increase his activity in this area as a ‘second career’.

James is active in Toastmasters (1998 – present). He was the president of the Sanofi club for a number of years, has achieved Advanced Communicator Gold, and has competed in Toastmaster competitions (District 83 Tall Tale Tale Winner 2012).
Percy H. Carter, PhD  
Executive Director, Immunology Medicinal Chemistry, Bristol-Myers Squibb

Percy graduated with an A. B. in Chemistry from Dartmouth College in 1991. He received his doctorate in Organic Chemistry in 1998 from Harvard University, where he completed the total synthesis of Bryostatin 2 under the tutelage of Professor David A. Evans. After completing a one-year postdoctoral fellowship in the pharmacology of G protein-coupled receptors at Harvard Medical School, Percy started his industrial career at DuPont Pharmaceuticals, reporting to Dr. Carl P. Decicco. His research focus was on approaches to the treatment of autoimmune and inflammatory disorders, which he maintained after the acquisition by Bristol-Myers Squibb. He joined the group of Dr. Joel C. Barrish in 2003, at the Princeton, NJ research site. Working with multi-disciplinary teams at BMS, Percy and his colleagues have advanced multiple compounds into human clinical trials. Percy is a co-inventor on over 20 issued U. S. patents and a co-author of more than 40 peer-reviewed publications. He is currently Executive Director of Immunology Medicinal Chemistry at Bristol-Myers Squibb.

RuiPing Dong, MD, PhD  
Senior Vice President, Head of Emerging Markets R&D, Merck & Co.

RuiPing Dong, M.D., Ph.D. joined Merck in December 2010 as senior vice president, head of Emerging Markets R&D. RuiPing is a member of the Emerging Markets Leadership Team (EMLT) and a board member for Merck-Sun Pharm joint venture and for BeiGene. RuiPing joined Merck from Bristol-Myers Squibb (BMS) where he was vice president and head of R&D for Japan and China.

As the head of MRL Emerging Markets, RuiPing leads new approaches for the clinical development and registration of late-stage programs so that they meet the needs of the local markets in Emerging Markets, especially for Brazil, Russia, India, China, Korea, Turkey and Mexico (BRICK-TM). He defines the activities that support global commercialization of branded generics, follow-on biologics, vaccines, extensions of Merck’s mature brands and innovative products. He also serves as the MRL representative for diversified brands. In addition, RuiPing is responsible for developing partnerships and capabilities to augment our discovery and development efforts in the emerging markets, benefit our global pipeline, boost overall productivity and differentiate us from the competition.

While at BMS, RuiPing was initially responsible for R&D in Japan, later expanding his role to include Asia-Pacific and emerging markets. Most recently, he assumed responsibility for building the company’s China R&D strategy and organization. He has an established track record for setting and delivering on a growth strategy in these markets. Prior to joining BMS, RuiPing worked at AstraZeneca in several roles in Clinical Pharmacology and Oncology, including Medical Director of Oncology in the United States and Product Team Leader for IRESSA in Japan where he led the first worldwide approval of IRESSA.

RuiPing earned his M.D. from Jiangxi Medical School in China, and his Ph.D. from Kyushu University Medical School in Japan. Before he joined the pharmaceutical industry, he worked as a Research Fellow at the Dana-Farber Cancer Institute at Harvard Medical School.
Glen Gaulton, PhD
Chief Scientific Officer and Executive Vice Dean, Professor of Pathology and Laboratory of Medicine at the University of Pennsylvania, Perelman School of Medicine

Glen N. Gaulton, Ph.D. is the Executive Vice Dean and Chief Scientific Officer, and Professor of Pathology and Laboratory of Medicine at the University of Pennsylvania’s Perelman School of Medicine. Dr. Gaulton’s responsibilities are to oversee both the Office of the Executive Vice Dean and Chief Scientific Officer and his active research laboratory. The Executive Vice Dean and Chief Scientific Officer leads the School’s research and research training enterprise and is responsible for both stimulating new research endeavors and providing the optimal intellectual and administrative support for ongoing research programs. This includes the Office of the Executive Vice Dean and Chief Scientific Officer, Biomedical Graduate Studies, Biomedical Postdoctoral Programs, Combined Degree and Physician Scholar Programs, Corporate Alliances, Human Research, Global Health, Masters Programs, and Research Program Development.

Dr. Gaulton received his Ph.D. in biochemistry and molecular biology from the University of California, Santa Barbara. He conducted postgraduate research in immunology at the School of Public Health and School of Medicine at Harvard University. Dr. Gaulton was appointed Assistant Professor of Pathology and Laboratory Medicine in the School of Medicine at the University of Pennsylvania in 1985, he was subsequently appointed as Associate Professor with tenure and is currently full Professor. Dr. Gaulton was appointed Associate Dean and Director of the Combined Degree and Physician Scholar Programs in 1993, Director of Biomedical Graduate Studies in 1995, Vice Dean for Research and Research Training in 1998, and Executive Vice Dean and Chief Scientific Officer in 2006.

Dr. Gaulton’s research interests are in the area viral pathogenesis. This work centers on a molecular description of the mechanisms that control retrovirus induced cell fusion and the detection of virus particles through nanotechnology. Dr. Gaulton has published over 100 manuscripts and texts, and directly supervised the research training of over thirty graduate students and fellows.

Dr. Gaulton serves on the Board of Directors of three organizations, is a reviewer for nine scholarly journals, and has been chair of five NIH study sections. Dr. Gaulton has received numerous awards for teaching and research, including the Dean’s Award for Basic Science Teaching, the Berwick Memorial Teaching Award, the Lindback Award, the Harry Weaver Neuroscience Scholar Award from the National Multiple Sclerosis Society, and the Leukemia Society Scholar Award.

Dahai Guo, MS, MBA
CEO and Founder, PuraCap Pharmaceuticals

Mr. Dahai Guo is the Founder & CEO of PuraCap Pharmaceutical LLC. and also the founder of Enspire Group.

Under Mr. Guo’s leadership, PuraCap Pharmaceutical is developing, manufacturing and marketing broad range of Rx and OTC pharmaceutical products in the global markets.

Through his 20-year professional career, Mr. Guo has held senior positions in several multi-billion dollar global companies and also start-up companies in biotech, pharmaceutical and healthcare product industry.
Mr. Guo has broad experience in sales & marketing, product development, global strategic planning and biotechnology research. He has demonstrated strong leadership in successfully marketing global healthcare brands and over 2000 different products in 90 different countries, including major retail markets like US, Canada, West Europe, Australia and China & India markets. Particularly, his strong marketing expertise has covered every sales channel in US retail (Food/Drug/Mass/e-commerce/C-stores), hospital and industrial (B-2-B) markets. His broad and hands-on experience also enabled him to build and grow New Jersey based pharmaceutical company, PuraCap Pharmaceutical LLC and its China based Joint Venture, Humanwell PuraCap (Wuhan) Pharmaceutical Inc.

Before he came to US, Mr. Guo conducted molecular biology research at China’s top research institute, Chinese Academy of Sciences in Beijing. Mr. Guo has MBA from Cornell University and M.S. of Biology from Rutgers University. He also completed distinguish Six-Sigma Black Belt training, awarded by America Society for Quality.

Sean Hu, PhD, MBA
Special Representative of Personalized Medicine Consortium, & Managing Partner and Head, Bionest Partners (USA)

Dr. Hu is Managing Partner and Head of US of Bionest Partners, a premier global life science strategy / management consulting firm with local presence in the US, EU and Asia. Dr. Hu is a recognized world class thought leader in the field of personalized medicine (PM) strategy. An early participant of the Human Genome Project, Dr. Hu is also one of the pioneers in advancing the PM business field. He has accumulated rich strategic consulting experience supporting global pharmaceutical and diagnostics industries on how best to develop and commercialize PM drugs and diagnostics. He takes pride in leading the effort to have developed corporate PM strategies, refined PM R&D and commercialization processes and built internal PM capabilities for a number of major pharma.

Dr. Hu is an invited speaker at many conferences, and with a significant list of published articles on the subject of PM. He is a contributor to Decision Analysis Handbook, in which he illustrates how to apply business decision analytics to addressing PM strategic issues. As part of his extracurricular activities, he holds an Adjunct Professor position at the Chinese National Human Genome Center (Shanghai), Chinese Academy of Sciences (CAS), and Senior Advisor & Visiting Professor positions at the Beijing Genomics Institute (BGI). He is also an Editor of the peer-reviewed journal Personalized Medicine and serves on the Dx and PM Committee of BioNJ, the PM Policy Committee of PMC, the Coalition to Strengthen the Future of Molecular Diagnostics, and previously the only representative from the Management Consulting industry invited to the FDA Personalized Medicine Initiative.

Dr. Hu obtained his PhD in Genomics from New York University, and an MBA from the Wharton School of Business, University of Pennsylvania.

Zhihe (Zeke) Li, MD, PhD
Senior Vice President, Corporate Development and Global Project Management, Frontage

Dr. Zhihe (Zeke) Li is one of the founders and Board of Directors of Frontage Laboratories, Inc. As Senior Vice President, he is responsible for Corporate Development and Global Project Management.

Dr. Li received his medical degree from Norman Bethune University of Medical Sciences in China and a PhD in Pathology from McGill University, Canada. After post-doctoral training at the National Institutes
of Health, he jointed and had been working in pharmaceutical/biotech industry for more than 15 years. Dr. Li has extensive experience in research and development for small molecule, peptides and protein drugs. In his academic and industrial tenure, Dr. Li has proven record to show his scientific achievement in biomedical research and pharmaceutical development. Dr. Li has been authored and co-authored more than 40 scientific papers and patents.

**Feng (Frank) Li, PhD**
President and Co-Founder, Alliance Pharma, Inc.

Dr. Li obtained his Ph.D. in Bioanalytical Chemistry jointly from Canadian Doping Control Centre and Concordia University. Subsequently he received post-doctoral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry.

Professionally, Dr. Li has held responsible roles in the area of drug discovery metabolism at MDS Pharma Services (a major CRO), in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GSK Pharmaceuticals and in the Drug Metabolism group at Cephalon. Dr. Li has extensive DMPK experience in both drug discovery and development. He is a recognized expert in the field of bioanalysis and DMPK. He has more than 15 years of working experience in CRO, pharmaceutical and biotech industries.

**Yingrui Li**
CEO, BGI Americas Corp. & CEO, BGI Tech Solutions, Co. Ltd.

Yingrui Li is CEO of BGI Tech Solutions and BGI Americas. He served as Director of Science & Technology at BGI from 2011 to 2012. In the past few years, he engaged or organized a number of international projects including Yan Huang Project, 1000 Genomes Project, Yan Huang Whole Genome Methylation, and Cancer Genome Project, etc. Yingrui has published thirty-six papers in high-impact journals including Nature and Science. He has received many awards and honors including Top 10 Scientific Achievements in China in 2010 and National Elitist in Shenzhen in 2009. He graduated from Peking University in the year of 2008.

BGI, formerly known as the Beijing Genomics Institute founded in 1999, is recognized as the world’s largest genomic center. Based on its massive next generation sequencing and bioinformatics resource, BGI aims to develop research collaboration and provide scientific support, contributing to the advancement of innovative biology research, molecular breeding, pharmaceutical, healthcare and related fields.

**Carlo Russo, MD**
Senior Vice President, Alternative Development Program, Head of ADD Development & Interim Head, Rare Disease R&D, GlaxoSmithKline

Dr. Russo has a range of academic, scientific, biotech, and pharmaceutical industry experience. He earned his medical degree from the University of Genoa Medical School and is board certified in hematology. After Clinical training in oncology, he pursued research in molecular immunology as a fellow at the Scripps Research Institute in La Jolla, CA and subsequently held a series of academic appointments at the College of Physicians and Surgeons, Columbia University, and at Cornell University Medical and Graduate Schools, where he still serves as an Adjunct Associate Professor. He has published
extensively on functional and molecular characterization of the major histocompatibility complex, cell-mediated immune response, tumor immunology, and the immunobiology of aging. Dr. Russo is a founding member of the National Institutes of Health, Geriatrics & Rehabilitative Medicine Study Section.

Prior to joining GSK, Dr. Russo was the President and Chief Executive Officer, VaxInnate Corporation, a start up Biotechnology Company which develops and manufactures vaccines and vaccine technologies. Dr. Russo raised $30M series B Venture Capital Funds to finance the development of VaxInnate’s first project; an M2e universal influenza vaccine against pandemic flu. In 2011 VaxInnate received $196 million from DARPA to develop the influenza vaccine. The vaccine Phase I studies are ongoing. He previously served as Executive Director and Head, Department of Global Strategic Regulatory Development, Merck Research Laboratories, where he oversaw and ratified development of global regulatory strategy for all vaccines and biologics. During his time at Merck, Dr. Russo was responsible for all regulatory filings in the US and worldwide for new vaccines, including those for HIV, human papilloma virus, Gardasil®, and rotavirus vaccine, Rotateq®.

Dr. Russo was recruited at GSK to develop an Alternative Development Program focusing on the development of albiglutide, a GLP-1 mimetic drug for Type 2 Diabetes. In addition, he was a founding member of GSK Biopharm R&D Unit. In that function, Dr. Russo was responsible for the development of all GSK Biopharm products in all therapeutic areas where he was responsible for development for 6 Phase III Biopharmaceutical Programs in therapeutic areas ranging from T1DM to CLL, to MS and RA.

Currently, Dr. Russo is Senior Vice President, Alternative Development Program, Development Head, Alternative Development & Discovery and Interim Head, Rare Disease Development for GlaxoSmithKline.

Joan Huaqiong Shen, MD, PhD
Chief Medical Officer, Hengrui Pharmaceutical Co., LTD

Joan began her career as a surgeon in China. She obtained PhD and became a board certified psychiatrist in US. She also obtained postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She gained her broad clinical drug development experiences in Eli Lilly, Wyeth and Pfizer, where she was responsible for global clinical development of multiple compounds with multiple indications cross phase 1-4. As the program lead, she was able to apply novel methods, including adaptive trial design, for novel compound development. She has extensive experiences working with FDA, EMEA, SFDA, PMDA, KFDA and etc. She also contributed successful NDA submissions. She also holds an academic position as the adjunctive professor in Indiana University School of Medicine.

Joan has been very devoted to Asian global clinical development. She was sent to Shanghai by Pfizer in 2011 as the China clinical lead and recently joined Hengrui as the chief medical officer.

Richard Soll, PhD
Senior Vice President, Integrated Services and Head, Corporate Alliances, WuXi AppTec

Dr. Richard M Soll is SVP, Integrated Services and Head of Corporate Alliances at WuXi AppTec, a Shanghai headquartered and New York Stock Exchange listed (NYSE: WX) premium provider of pharmaceutical R&D services across. In this capacity, Dr. Soll has advanced more than 30 programs across major target classes and therapeutic
indications from hits into lead optimization campaigns, giving rise to clinical candidates on behalf of WuXi customers in pharma and biotech. In addition, Dr. Soll heads Corporate Alliances Office at WuXi, oversees strategic partnering activities with our global partners in designing and executing creative collaboration models to maximize R&D productivity and shorten time to market.

Previously, WuXi, Dr. Richard Soll was CSO and VP, R&D at TargeGen where he led innovative clinical-stage R&D programs for isoform-specific PI3K inhibitors as therapeutics for inflammation, respiratory disease and cancer, multi-targeted src/VEGF inhibitors as the first topical kinase inhibitors AMD, and highly selective JAK2 inhibitors for the treatment of myeloproliferative disorders, the latter leading to the acquisition of TargeGen by Sanofi. Dr. Soll founded the chemistry department 3-DP as VP, Chemistry. Dr. Soll spent 10 years at Wyeth Pharmaceuticals, and trained as a synthetic chemist at Dartmouth and Harvard.

Dr. Soll's drug discovery and development experiences has led to more than 7 drug candidates entering and advancing the clinic for infectious disease, cardiovascular disease, cancer, and ocular indications up to pivotal trials. Dr. Soll's patent and publication record in peer reviewed journals has produced more than 100 patents and papers. Dr. Soll has been an SAB member in biotech and advisor to entrepreneurs.

Anthony Sun, MD, MBA
Partner, Aisling Capital

Dr. Sun joined Fund I in 2002 and currently serves as a Partner of Aisling Capital. Previously, Dr. Sun was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania. Dr. Sun currently serves as a director of several healthcare and life science companies. He received his M.D. from Temple University School of Medicine with A.O.A. honors. He received his M.B.A. from The Wharton School at the University of Pennsylvania, and his B.S. in Electrical Engineering from Cornell University. In addition, he is Board Certified in Internal Medicine.

Steve Z. Sun, PhD
CEO and Chairman, Genewiz

Dr. Sun is the Chairman and CEO of GENEWIZ, Inc., the company he co-founded in 1999. GENEWIZ is a contract research company that specializes in genomics services including DNA sequencing, gene synthesis, translational genomics, molecular biology, and GLP/GMP standard genomics services. GENEWIZ has established a global network of laboratory operations in New Jersey, Maryland, North Carolina, Massachusetts, Washington and California in the US, and Beijing and Suzhou in China.

Dr. Sun obtained his Bachelor and Master degrees from Tsinghua University in Beijing. He obtained his Ph.D. from Columbia University in the City of New York. Dr. Sun received his postdoctoral training at the Rockefeller University. Starting GENEWIZ, Inc. is his first job after that.

Dr. Sun serves as a member of the Board of Directors at Frontage Laboratories since its founding in 2000, the Innovation Sounding Board of Rutgers University’s Center for Innovative Ventures of Emerging Technologies (CIVET), and the Advisory Board of the Commercialization Center of Innovative Technology (CCIT), a New Jersey (State) Economic Development Authority (NJEDA) organization. Dr. Sun received the Ernst & Young 2010 Entrepreneur of the Year Award in New Jersey.
The Ernst & Young award recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses.

GENEWIZ was named as the Business of the Year (2011) in the 100+ Employees category by NJBIZ, and received an Award for Excellence in the business expansion category from the New Jersey Business Industry (NJBIA) in 2011. GENEWIZ was ranked 28th amongst New Jersey’s 50 Fastest Growing Companies by NJBIZ in 2011. Independent marketing researching firm Frost & Sullivan selected GENEWIZ, Inc. as the recipient of the Growth Strategy Leadership Award, in recognition of its high quality services and unparalleled support in the North American DNA sequencing services markets.

Peng Wang, PhD  
President, R&D, Yabao Pharmaceutical Group

Dr. Peng Wang, a member of the China National “1000-Talents Program”, is currently the President of R&D of Yabao Pharmaceutical Group. Previously, he was Chief Scientific Officer of Simcere Pharmaceuticals Group, a leading Chinese pharmaceutical company headquartered in Nanjing, China (simcere.com; “SCR” at NYSE). Prior to joining Simcere, Dr. Wang was with WuXi PharmaTech, a leading pharmaceutical CRO in China, as Vice President of Discovery Biology in 2008-2009. Before joining WuXi PharmaTech, he worked on discovery through early clinical development for Schering-Plough in New Jersey, USA for 18 years. Dr. Wang has made significant contributions to the discovery and early development of 16 drug candidates in US and China, and also to the establishment of several collaboration partnerships between Simcere and US companies. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J. etc. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, and his B.S. in Medicinal Chemistry from the China Pharmaceutical University.

Haishan Xiong, PhD, MBA  
President and Co-founder, Vitalico LLC

Dr. Xiong is COO and co-founder of Vitalico LLC, a consumer healthcare startup. Under his leadership, Vitalico has established a strong market position in weight loss and health management among consumers. Dr. Xiong has many years of experiences in commercial operations in the Biopharma industry. Prior to Vitalico, he was the Federal segment director at Spectrum Pharma. He led Spectrum’s strategic development and commercial efforts to the Federal government. Dr. Xiong started his pharma career at Roche, rising from analyst to various leadership positions in marketing and sales. Dr. Xiong is a Life-time Member of SAPA and former Executive Committee Member.

Dr. Xiong obtained his MBA from Wharton School, his PhD in Physiology from Penn State University, and his BS in Molecular Biology from Nankai University.

Zhengbin (Bing) Yao, PhD  
Senior Vice President and Head, Innovative Medicine, MedImmune, AstraZeneca

Dr. Zhengbin (Bing) Yao joined MedImmune USA, the biotechnology division of AstraZeneca, in 2010 as Senior Vice President of research and development and
head of the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit. In this role, he leads the franchise and a cross-functional team dedicated to the advancement of the company's RIA portfolio.

An accomplished executive and scientist with more than 19 years of experience in the biotechnology and pharmaceutical industry, Dr. Yao previously led the project team leaders' group for immunology, central nervous system, virology and metabolism for Genentech. Prior to Genentech he served as Vice President of Research and Corporate Officer for Tanox, and held roles of increasing responsibility at Aventis and Amgen. Dr. Yao was instrumental in advancing many biologics from discovery to IND and to different stages of clinical development.

Dr. Yao received his doctorate in microbiology and immunology from the University of Iowa. In addition, Dr. Yao has authored more than 50 publications and holds over 20 patents and patent applications.

**PK Yegneswaran, PhD**
Vice President, Global Technical Operations, Merck & Co., Inc.

Dr. PK Yegneswaran is currently the VP of Global Technical Operations at Merck & Co., Inc. In this role, he is responsible for providing manufacturing technology support to Merck's global internal and external small molecule supply network including Emerging Markets, External Manufacturing partners and Suppliers. He has 22 years of bio pharmaceutical industry experience in various leadership roles supporting late stage development, commercial supply, technology transfer, strategic initiatives, continuous improvement, change management and integration across small molecule and vaccine products.

PK has a BS and Ph.D in Chemical Engineering from the Indian Institute of Technology and the University of Alberta respectively.

**David Zeng, PhD**
Co-Founder & Board Member, Nuron Biotech, Inc.

Dr. Zeng is co-founder and Board member of Nuron Biotech Inc, located in Exton, PA since its inception in Dec 2009. He served as Chief Scientific Officer & Senior Vice President, Research & Development at Nuron Biotech until May, 2013. Nuron Biotech is a rapid growing premier biopharmaceutical company with focus on development and commercialization of biologics and vaccines. Its commercial product – Meningitec, a pediatric vaccine for meningitis, is marketed in more than 20 countries in Europe. Its lead product under development – Relonsiv, an improved interferon beta-1b, is currently in Phase 3. Other biologics and vaccines in the pipeline include long acting interferon beta-1b, therapeutic vaccines for Hepatitis B, C, and Alzheimer’s disease.

Dr. Zeng is a biotech veteran with 16 years of industrial experience in development of biologics. He served as the head of development at BaroFold in Boulder, Colorado until 2009. Prior to joining Barofold in 2007, he worked at Pfizer Biologics R & D for 10 years in various roles of increased responsibility including as Associate Director for CMC functions and Development Team Leader for late stage development projects. He made significant contributions in the approval of Somavert, Macugen and development of Cimzia.
Dr. Zeng obtained his Ph.D. in Pharmaceutical Sciences from the University of Connecticut.

Litao Zhang, PhD
Vice President, Lead Discovery, Lead Profiling, Lead Evaluation, Mechanistic Biochemistry & Compound Management, Bristol-Myers Squibb

Litao received her Ph.D. degree in Biochemistry and Yeast Genetics from Washington University School of Medicine, St. Louis and completed her post-doctoral training in the Department of Pathology at the University of Pennsylvania.

She joined BMS in 2003 and prior to that, held positions of increasing responsibility at Aventis and DuPont Pharmaceuticals. Since 2003, Litao successfully established and led the Lead Evaluation function across three research sites through the Leveraging Technology Initiative. The first-in-class technology platforms and novel informatics solutions developed by this cross-functional team led to a significant paradigm shift and repositioned BMS technology infrastructure at the frontier of two major drug target classes, kinases and G-protein coupled receptors for lead optimization. The revolutionary lead optimization process resulted in a 20-fold productivity increase and a 3-fold cycle time reduction for in-vitro pharmacology data packages. This in turn empowered quicker, more informed decisions on the chemical synthesis strategy and influenced selection of high quality drug candidates earlier in the lead optimization process. During the last five years, she also transformed the Mechanistic Biochemistry team from operating obsolete technology platforms to leading advanced technology platforms with a focused mission and increased capacity to impact the BMS portfolio.

Since 2009, she further expanded her leadership influence within and beyond R&D. As a key member of the Research India implementation team, she provided key implementation plans to establish the in-vitro pharmacology group in India. She was responsible to recruit functional heads and key team members. In 2010, she was able to successfully transition the pharmacology and technology functions to the local leaders in India. Today, she serves as a core team member and provides an advisory role for BMS India Research Center. In 2011, she became one of core team members to develop the BMS China 2020 strategy together with the Emerging Market leaders. During the past two years, she developed and championed a differentiated Research China strategy. This approach transformed BMS Research models from ad hoc and need-based to strategic, expert centric and long-term partnerships through academic collaborations for innovative science and integrated strategic partnerships for pipeline sustainability in China. In 2012, she engaged 1st class scientists at China’s top university, Tsinghua University, and delivered the first BMS academic alliance supporting oncology and immunology drug discovery efforts in China.

Recognizing her accomplishments at BMS, she was awarded the Ondetti Cushman Innovation Award in 2007, the Biopharma Leadership Award in 2011 and the Jack Grebb Excellence in Leadership Award in 2012. Currently, she is one of research funding review committee members for National Institutes of Health (NIH) and reviewed over hundreds of the proposals for major NIH initiatives including Drug Screening and Therapeutics for Rare and Neglected Diseases and NIH roadmap Small Molecular Screening. In 2011, she became one of the founders for the International Chemical Biology Society. She has over 30 scientific publications and is actively involved in a number of scientific communities.

De-Min Zhu, PhD
President & CEO, Cureport, Inc.

De-Min obtained his Ph.D. degree in Physical Chemistry at Peking University. After 6 years of cross disciplinary postdoctoral research at NIH and Harvard Medical School in biochemistry, biophysics, cell biology, immunology, and cancer research, he
committed his career to pharmaceutical industry. In 2000, De-Min joined Merck to lead vaccine formulation and therapeutic siRNA formulation groups, and developed more than 20 biologic formulations and processes for phase I to phase IV clinical studies, including vaccines for HIV, cancer, influenza, and zoster, and RNAi therapeutics. Those formulations involved proteins, peptides, live or inactivated virus, DNA, siRNA, and varieties of polymer- and lipids-based nano particles. In 2009, De-Min was hired by Pfizer as a Research Fellow, head of Delivery Formulation of Oligonucleotide Therapeutics. While representing the formulation department in multiple product teams, he conducted numerous projects in close collaboration with clinical, regulatory, bioprocess, bioanalytical, manufacturing, CMC, and marketing departments to ensure the program to meet with milestones. At Merck and Pfizer, De-Min also acted as a core member in technology license committees of RNAi therapeutics, evaluated over 400 external nanotechnologies, and participated in numerous important licensing due diligence and go/no-go decision making for technology and company acquisitions.

With the strong support of a VC investment, De-Min founded Cureport, Inc. in the United States, and assumes the office of President and CEO. He invented the proprietary nPortTM platform nanotechnology that provides a robust process for the manufacture of nano particles for small molecule and biologic drug delivery. Utilizing nPortTM technology, Cureport develops nano formulations targeting cancer and infectious diseases.

De-Min is one of the co-founders of SAPA-GP, and continuously makes valuable contributions to SAPA in promoting pharmaceutical collaborations between the US and China. De-Min has published over 30 publications in peer-reviewed scientific journals. He established the first mathematical method in the world for the study of two dimensional interactions of cell surface proteins at cell-cell contact area. This method was cited in the literature as the Zhu-Golan Equation.
Sponsors

City of Tai Cang
江苏太仓市
GENEWIZ
Solid science. Superior service.

Your Genomics Service Provider:

- Translational Genomics
- CLIA Certified, CAP Accredited, GxP Compliant
- Next Generation Sequencing
- Gene Synthesis
- Sanger DNA Sequencing

SPECIALIZING IN GENOMICS SINCE 1999
1-877-GENEWIZ
www.genewiz.com
BGI Tech, a subsidiary of BGI - the world’s largest genomics organization, is a leading provider of next-generation sequencing and bioinformatics analysis services for global customers. Equipped with the industry’s broadest array of cutting-edge technologies, BGI Tech delivers rapid, cost-effective, and high-quality results that enable researchers to achieve scientific breakthroughs.

**Full Range of Services to Meet Your Research Needs**
- Whole genome sequencing
- Whole exome sequencing
- Target region sequencing
- Metagenomics
- RNA-Seq (Transcriptome)
- RNA-Seq (Quantification)
- Small RNA sequencing
- Quantitative proteomics
- Target proteomics (MRM)

**Advanced Technology Platforms**
- Sequencing Platform
- Proteomics Platform
- Cell Biology Platform
- Bioinformatics Platform

---

**Expertise and Experience**
- Recognized as a world leader in DNA, RNA, and protein analysis
- Over 250 publications in top-tier journals
- Sequenced more than 1,000,000 samples
- Over 1,000 bioinformaticians to analyze your data

**Turn-around Time, Quality and Price**
- No project is too big for us
- Rapidly complete projects with uncompromised quality
- Exceed your project pricing expectations

**Continuous Innovation**
- Selected as World’s Top 10 Most Innovative Companies in China
- Continuously developing new technologies including bioinformatics software SOAP

**Reliability and Security**
- Strong quality control and assurance
- Extremely robust data security system
- ISO 9001:2008 certified, Illumina CSPro certified and Agilent SureSelect certified

---

**GenScript GP Area Contacts**
Linda Jesse, Business Development Manager / 732-453-4661
Nicole Niu, Regional Sales Manager / 732-902-1603

**Dedicated Biology CRO:**
- Leading gene synthesis provider in USA
- Best antibody guarantees in industry
- One-stop services focusing on pre-clinical drug discovery
- Global presence and local access

**Reliable Drug Discovery Partner:**
- Full customer IP protection
- ISO certified, cGMP compliance, and AAALAC accredited
- Project-based, FTE-based, and Strategic Alliance
- Seasoned scientific and management team

---

**CUSTOM REAGENT**
- Molecular Biology Services
- Custom Peptide Services
- Protein Expression Services
- Custom Antibody Services
- Cell Line Development Services

**ANTIBODY DRUG DEVELOPMENT**
- Antibody Engineering
- Bioprocess Development
- Bio-Assay Service
- Animal Model Service

---

**CATALOG PRODUCTS**
- Nucleic Acid Preparation & Analysis
- Catalog Antibodies
- PCR & Cloning
- Peptide & Biochemicals
- Protein Expression, Isolation & Analysis
- Cellular Analysis

---

www.genscript.com

---

Cureport, Inc. is a growing pharmaceutical company committed to the development of nano technologies for formulations of medicines. With a strong VC investment, Cureport has established its proprietary nanoparticle technology platform, nPort™, for drug delivery of both small molecules and biological molecules for the treatment of cancer, infection and metabolic diseases. The company has developed series of nano formulations to dramatically improve tumor-targeting drug delivery, enhance efficacy and reduce toxicities. The production process based on the nPort™ technology is amenable to GMP commercialization scales. Cureport develops its core technologies in-house, and contracts with CRO/CMO for regular research and GMP productions.

The cutting-edge technology platform, nPort™, developed by Cureport opens two major avenues of pharmaceutical product R&D: 1) quickly establishing pipelines of novel formulations of existing or new drug substances with greater efficacy and much lower toxicity; 2) utilizing this platform technology to produce generic nano medicines with a robust process and much lower cost than the traditional technology. One of the applications of the nPort™ technology is the manufacture of liposomal drugs. The nPort™ technology platform enables the company to produce high quality liposome formulation in a scale of multi kilograms of lipids in a single batch in a single day. As an example of application of this technology, Cureport has successfully established a production system for liposomal doxorubicin that generates the product identical to the commercial medicine Doxil.

Currently the company is located on the campus of Worcester Polytechnology Institute at 60 Prescott St. Worcester, MA 01605. For enquiries of the company information, please email to info@cureportinc.com.
Alliance Pharma
Your Trusted Partner

CORE CAPABILITIES
Alliance Pharma is a Contract Research Organization (CRO) specializing in bioanalytical services for both small and large molecules, and drug metabolism. Our extensive and diverse industrial experience includes:

- Analysis of drugs, agrochemicals and food ingredients
- Small molecule LC-MS/MS analysis
- Large molecule immunoassays
- Cell based assays
- Drug metabolism studies: drug-drug interactions (inhibition, induction), metabolic stability and protein binding

www.AlliancePharmaco.com

Our projects must be completed on time and on budget.

We depend on Frontage.

DMPK
Biologics Services
Bioanalytical Services
Regulatory Consulting
Clinical Trial Materials
CMC Drug Development
Clinical Phase I/II Studies

For more on our fully integrated CRO Services, contact us at
sales@frontagelab.com
www.frontagelab.com
610-232-0100
康缘药业国家重点实验室诚邀海外高端医药人才加盟

Kanion Pharma Invites Overseas Biomedical Experts to join its Key National Laboratory

江苏康缘药业股份有限公司，位于江苏省连云港市，在北京和南京设有分部，是中国国家新医药产业化基地的重点骨干企业、国家中药现代化示范企业、国家重点高新技术企业、国内社会公众股（A股）上市公司。康缘药业承担的国家重点实验室正在进行积极寻求全球医药行业优秀的研发项目，并以项目为载体，通过项目支持与合作，引进不同背景、握有核心技术或研发项目的优秀人才。

1. 研究与开发方向 各个研究阶段、各个治疗品种的中药、化药、生物药的创新药物研发项目，及与新药研发、生产相关的关联新技术、新辅料的开发项目等。

2. 项目合作机制 面向全球全时开放，随时申请，随时受理。项目入选后将纳入国家重点实验室合作项目管理，本平台将按阶段提供项目的研发经费、场所、仪器设备，创新团队可以自由选择平台或单独申请，平台也可以依托平台专业研发人员执行项目开发。若创新团队无法常驻中国，可以在本地或外部自由选择有能力胜任者，经技术转移途径以委托方式进行研发。或采取双方协商均能接受的其他合作形式进行研发。

3. 人才加盟方式 申请人向康缘药业提出申请后，经康缘药业审核决定聘用的人才，可以自由选择加盟的形式、可以以个人、合作者、或项目团队的方式加盟，双方签订聘用合同。

4. 互利共赢对于引入的产品以及引入后所取得的成果，项目持有人仍然拥有所有权和发明专利权，康缘药业享有专利许可、专利使用的优先权。对于康缘药业引新研发成果，双方签订技术转让合同，项目持有人可选择在扣除研发投入的成本费后，康缘药业向原创新人一次性支付可用于项目技术转移的奖金，项目持有人也可选择技术入股的方式持有一定的比例的项目分红权。对于康缘药业不获让的研发成果，可对外进行技术转让，转让所得在扣除研发投入的成本费后双方按4:6比例分获，即创新人获得40%，康缘药业获得60%。

联系方式：
张怡博士
Yi Zhang PhD
E-mail: yizhang@kanion.com
Web: www.kanion.com
Mobile: +86 186 5207 1871

周晓峰
Xiaofeng Zhou
E-mail: xiaofeng.zhou@kanion.com
Mobile: +86 13961372870
Tel: +86 0518-85521996

滕苏扬
Teng Suyang
E-mail: tengsuyang@126.com
Tel: +86 (518) 8552 1975
Mobile: 15905139282